6 Endocrinology Headlines You Missed in January 2026

During January, endocrinology saw a slew of medical and technological approvals and advancements. The US Food and Drug Administration (FDA) cleared the MiniMed Go Smart Multiple Daily Injection (MDI) app for patients ≥7 years with type 1 diabetes (T1D) or type 2 diabetes (T2D), as well as approving an updated starting dose guideline for inhaled insulin powder in T1D. Diabeloop received clearance for its DBLG2 algorithm and has since partnered with Sequel Med Tech to integrate the program with the Twiist automated insulin delivery system.

With so many stories in the past 31 days, the HCPLive editorial team has collected 6 of the most impactful headlines from January 2026. Catch up on any news you might have missed below.

FDA News

FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)

On January 26, 2026, MannKind Corporation announced the FDA’s approval of an updated label for insulin human inhalation powder to provide guidance for starting dosages when switching from multiple daily injections or insulin pump mealtime therapy for T1D. The approval was based on data from the phase 4 INHALE-3 trial, which showed improved postprandial glucose outcomes after converting to inhaled insulin with this conversion dose.

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

On January 12, 2026, the FDA granted 510(k) clearance to Medtronic’s MiniMed Go Smart MDI app for use in patients aged ≥7 years – and for children between 2 and 6 years under adult supervision – with T1D or T2D. The system integrates the InPen smart insulin pen with the Instinct sensor from Abbott, all of which are connected via the MiniMed Go app.

FDA Accepts for Priority Review sBLA for Teplizumab for Children With Stage 2 T1D

On January 5, 2026, the FDA accepted for priority review the supplemental BLA for teplizumab-mzwv for delaying the onset of stage 3 T1D. Announced by parent company Sanofi, the application aims to expand the age indication from ≥8 years to ≥1 year. The application was based on positive interim 1-year data from the PETITE-T1D phase 4 study, which saw 23 patients enrolled with a mean follow-up of 51.9 weeks. After investigators recorded a probability of lack of progression to stage 3 of 89.6%, teplizumab was deemed safe and well-tolerated in children <8 years with stage 2 T1D. Teplizumab-mzwv is the first and only disease-modifying therapy in autoimmune T1D, initially receiving FDA approval in November of 2022.

Trial Data

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

On January 27, 2026, Genentech announced positive topline results from the phase 2 CT388-103 trial, which demonstrated CT-388’s efficacy in achieving substantial weight loss in patients with obesity. Of the 469 patients in the trial, 26.1% of patients receiving CT-388 achieved a weight loss of ≥30%, and 73% of patients with prediabetes achieved normal blood glucose at week 48. CT-388 was also well-tolerated during the trial. Genentech plans to present full results at an upcoming medical congress.

Podcast Updates

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

In this segment of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, met with Susan Weiner, MS, a nationally recognized dietician and diabetes care and education specialist, to discuss the newly released Dietary Guidelines for Americans 2025-2030. In particular, the trio focuses on the ambiguity inherent in the guidelines’ alcohol intake recommendations. Rather than specifying a limit like prior guidelines, the new document broadly suggests to “drink less.” Weiner, Isaacs, and Bellini break down the confusion caused by these guidelines.

Diabeloop’s DBLG2 and a Closed Loop With the Twiist Delivery System for T1D

In this segment of Diabetes Dialogue, Isaacs and Bellini spotlight a newly announced partnership between Diabeloop and Sequel Med Tech. The 2 companies joined together after Diabeloop was granted 501(k) clearance from the FDA for the DBLG2 algorithm, designed to automate and personalize insulin delivery for patients with T1D. The algorithm will be paired with Sequel’s automated insulin delivery system Twiist.